Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 12, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,450,000 Ordinary Shares of 25 pence each.
- Purchase Date: June 12, 2012.
- Price Range: Highest price paid was 1,453.5 pence per share; lowest price paid was 1,437.0 pence per share.
- Treasury Holdings (Settled): 457,957,927 shares (8.38% of total issued share capital).
- Treasury Holdings (Including Unsettled): 462,607,927 shares (9.24% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,007,368,626 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,450,000 shares, which were placed into Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 9.24% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,007,368,626) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the distinction between settled treasury shares (8.38%) and total treasury holdings including unsettled trades (9.24%).
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.